Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children. DESIGN: International, multicentre, phase II/III, randomized, open-label, noninferiority trial (KONCERT/PENTA18/ANRS150). SETTING: Clinical centres participating in the PENTA, HIV-NAT...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645961/
https://www.ncbi.nlm.nih.gov/pubmed/26558544
http://dx.doi.org/10.1097/QAD.0000000000000862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645961/
https://www.ncbi.nlm.nih.gov/pubmed/26558544
http://dx.doi.org/10.1097/QAD.0000000000000862

Ejemplares similares